Overview A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of MB1707 in Patients With Advanced Cancer Status: Not yet recruiting Trial end date: 2024-12-01 Target enrollment: Participant gender: Summary The study will evaluate the PK and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers. Phase: Early Phase 1 Details Lead Sponsor: Mainline Biosciences, Inc.